Skip to content

Medical Affairs

Intelligence Hub

Overview

Home
My Work
Command Center

Plan & execute

Medical Plans
Launch Readiness
Budget & Resources
Risks & Decisions

Field & science

Engagements
Insights
Evidence Generation

Communicate

Publications
Congresses
Medical Information

Govern

Reports
Data Quality
Administration

Helixor Therapeutics

Sample data · FY2026

Scope·4 products·FY2026

HODr. Helen OkaforGlobal Head of Medical Affairs

EngagementsENG-0046

Scientific exchange · Dr. Oscar Zimmermann

03 May 2026 · Phone · Dr. Oscar Zimmermann, UCSF Medical Center · MSL Rachel Adeyemi · Vantrexa

ReviewedVeeva CRMENG-0046—

Capture insight from this engagement

Location: UCSF Medical Center
Therapeutic area: Oncology
Country: United States
Stakeholder tier: Tier 2
Strategic objective: Not linked
Initiative: Not linked
MSL: RARachel AdeyemiMSL, Oncology (UK & Ireland)
Product: Vantrexa (vantrelimab)

Topics discussed

Sequencing after progression
Elderly / ECOG 2 patients

Scientific content used

VTX core scientific deck v3.2

Questions raised

How should grade 2 infusion reactions be managed without steroids?

Notes

Scientific exchange with thoracic medical oncologist at UCSF Medical Center. Discussed sequencing after progression, elderly / ecog 2 patients.

Insights captured (1)

Capture insight

INS-0073Medium
Sequencing after progression
Sequencing after progression: request for data reported by thoracic medical oncologist (US).
Closed

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

Share MI standard response

0 of 1 complete

Quality ratings

1–5, rated at review

Scientific relevance: 4
Strategic relevance: 4
Depth of exchange: 2
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0046

Audit history (0)

All create, update and approval events for this record

No audit events in sample data